FORM 4

obligations may continue. See

Instruction 1(b)

Check this box if no longer subject to Section 16. Form 4 or Form 5

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Washington, B.S. 20040

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Clancy Paul J							2. Issuer Name and Ticker or Trading Symbol BIOGEN IDEC INC. [ BIIB ]								applio recto	of Reporting Pe cable) or (give title		son(s) to Iss 10% Ov Other (s	vner	
(Last) (First) (Middle) BIOGEN IDEC INC. 133 BOSTON POST ROAD						3. Date of Earliest Transaction (Month/Day/Year) 02/08/2013									elow)		VP ar	below)		
(Street) WESTON MA 02493					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person					
(City)					-									Form filed by More than One Reporting Person						
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					action	ar) i	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			or 5. Amou 4 and 5) Securiti Benefic		nt of es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) or (D)	Price	Tra	nsac	u tion(s) and 4)			(Instr. 4)	
Common Stock 02/08/						2013					2,765	A	\$(	\$0 26,		,377		D		
Common Stock 02/08/3						2013					899	D	\$164	.44	25	,478		D		
Common Stock 02/09/3						3					4,692	A	\$(	)	30,170			D		
Common Stock 02/09/2						3					1,731 I		\$164	.44	28,439			D		
		7	able II -								osed of,				ed					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Executior if any (Month/Da	ed n Date,	4. Transactio Code (Insti		5. N of Deri Sec Acq (A) Disp of (I	umber ivative urities juired or posed D) tr. 3, 4	6. Date Exercise Expiration Date (Month/Day/Yea		sable and	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Prio Deriva Secur (Instr.	tive ty	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ve O Fe Di ally or (I) d tion(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	e V (A)		(D)	Date Exercisa		Expiration Date	Title	Amoun or Numbe of Shares	r						
Restricted Stock Unit	\$0	02/08/2013						2,765	(1)		02/08/2016	Common Stock	2,765	\$0		10,002	2	D		
Restricted Stock Unit	\$0	02/08/2013			J			426 <sup>(2)</sup>	(1)		02/08/2016	Common Stock	426	\$0		9,576		D		
Restricted Stock Unit	\$0	02/09/2013			M			4,692	(1)		02/09/2015	Common Stock	4,692	2 \$0		9,382		D		

## **Explanation of Responses:**

- 1. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).
- 2. This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

/s/ Aras Lapinskas, Attorney in Fact for Paul J. Clancy 02/12/2013

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.